With increasing death cases linked to medications manufactured in India and reported in other countries, the Indian Government has set a deadline for the mandatory implementation of World Health Organisation (WHO) – Good Manufacturing Practises (GMP) guidelines. The Indian Government has set a date for the mandatory adoption of World Health Organisation (WHO) – Good Manufacturing Practises (GMP) criteria for medications manufactured in India and reported in various nations.
It is worth noting that, in a surprising disclosure, Union Health Minister Mansukh Mandaviya recently stated that only 2,000 of the country’s total 10,500 pharmaceutical production facilities had been deemed to be in accordance with worldwide WHO-GMP standards. It is worth noting that just three of these conforming units are headquartered in Nagpur. The new GMP is now required to ensure the manufacturing of high-quality pharmaceuticals for domestic and foreign markets.
There are around 40 to 45 companies and 18 oxygen factories in the city, but only three companies, namely ZIM, LUPIN, and Sneha, have achieved WHO compliance in the Nagpur division. With the government’s efforts to align Indian pharmaceutical practices with international standards, it is hoped that additional manufacturing units, including those in Nagpur, will prioritise the application of WHO-GMP principles to assure pharmaceutical product safety and quality.
